Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 10.75p 10.50p 11.00p 10.75p 10.75p 10.75p 91,597 07:30:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.4 -3.1 - 9.82

Synairgen Share Discussion Threads

Showing 626 to 649 of 650 messages
Chat Pages: 26  25  24  23  22  21  20  19  18  17  16  15  Older
DateSubjectAuthorDiscuss
08/9/2017
01:43
https://www.youtube.com/watch?v=6uIXJ22ESb4 Pharmaxis on LOXL - well worth watching
ohisay
07/9/2017
16:54
15p tomorrow??
miahkaysor
07/9/2017
13:35
Good summary on proactive investors - still very cheap in my book with a EV of just £6m on my estimates - given the whole fibrosis space is underserved ATM. Not beyond the bounds of possiblity that a larger company could fund some of the phase 1 trial in return for some of SNG's 50% LOXL holding. And they appear to have not given up on the INFB route.
ohisay
07/9/2017
11:37
Looking even better today this.
412069
06/9/2017
15:02
From The latest SNG Presentation dated 10th March 2017... Synairgen and Pharmaxis collaboration • Develop an anti-fibrotic LOXL2 inhibitor for Idiopathic Pulmonary Fibrosis (IPF) • High LOXL2 is associated with more rapid disease progression • Recent deal in Fibrosis include: o Discovery stage  Boehringer Ingelheim 2016 collaboration with Inventiva to develop targets for IPF. Deal value up to €170m plus tiered royalties o Phase I  Gilead buys Nimbus Therapeutics in 2016 for Liver fibrosis programme $0.4bn up front and up to $0.8bn future payments o Phase II  Allergan buys Tobira Therapeutics in 2016 for Liver fibrosis programme $0.6bn up front and up to $1.1bn future payments  Bristol-Myers Squibb enters an agreement in 2015 providing exclusive rights to acquire Promedior Inc for up to $1.25bn o Post approval  Roche acquired Intermune in 2014 for $8bn, main programme was pirfenidone for IPF, and other anti-fibrosis programmes
rosejs2
06/9/2017
12:46
about to pop upwards again here.
412069
06/9/2017
08:22
these should go up today with this latest news i would assume?
nakedsteve
06/9/2017
08:05
It didnt move when it got the cash from boehringer either ! - it will only move when it gets a bid I think and thats entirely possible.
ohisay
06/9/2017
07:55
That's a catchy name: PXS-5382A The corresponding Pharmaxis announcement is here: http://www.asx.com.au/asxpdf/20170906/pdf/43m3bt3bsm1ljc.pdf Not much of a share price reaction for Pharmaxis following that update.
timbo003
06/9/2017
07:08
Really good news today Synairgen will progress PXS-5382A through the Phase I trial, the results of which are expected mid-2018. Thereafter Synairgen and Pharmaxis plan to out-license PXS-5382A to a suitable partner to fully realise the commercial value of this compound given the potential size and number of indications it could address. Richard Marsden, CEO of Synairgen, commented: "We believe PXS-5382A is a very valuable candidate with potential applications in a number of fibrotic conditions including lung, liver, cardiac and kidney fibrosis. These diseases represent areas of high unmet medical need and consequently present very substantial market opportunities. "The effect of this novel inhibitor across different model types is very exciting, with the latest supporting data suggesting that PXS-5382A can significantly reduce lung fibrosis and therefore has the potential to improve lung function in severely ill patients. These data build on the encouraging results seen to date and further support the rationale behind bringing this promising inhibitor to clinic. "Based on PXS-5382A's potential across a number of disease areas and the promising data seen to date, we have received significant interest from companies looking to license the programme for multiple indications. We look forward to progressing these discussions as PXS-5382A advances through the clinic.
ohisay
06/9/2017
03:10
From Pharmaxis - asx release today.Current SNG valuation is just beyond bonkers IMV (EV around 4m$ ?). I've been aggressively buying 10p down to 7p - should be back in double figures today I'd have thought ... hxxp://www.pharmaxis.com.au/investor-centre/news/view/anti-fibrotic-loxl2-program-clears-preclinical- development-and-set-to-commence-phase-1-trials Pharmaceutical research company Pharmaxis (ASX: PXS) and its collaborator UK biotechnology company Synairgen plc (AIM: SNG) today announced completion of the preclinical development stage of their anti-fibrotic Lysyl Oxidase type 2 (LOXL2) inhibitor program allowing the first compound to commence human clinical phase I studies in Q4 2017. The Pharmaxis drug discovery group has developed a number of selective small molecule inhibitors to the LOXL2 enzyme utilising the same amine oxidase platform that delivered PXS-4728A, an anti-inflammatory drug that was acquired by Boehringer Ingelheim in 2015. The LOXL2 enzyme is fundamental to the fibrotic cascade that follows chronic inflammation in the liver disease NASH, cardiac fibrosis, kidney fibrosis, and idiopathic pulmonary fibrosis (IPF), and it also plays a role in some cancers. Pharmaxis CEO Gary Phillips said, “The extensive pre‐clinical program performed on our program compounds has confirmed that they have all the characteristics of a successful once a day, oral drug. They have shown excellent efficacy in several different in vivo fibrosis models including fibrosis of the liver, lung, kidney and heart. These findings have been the subject of presentations at a number of international scientific conferences and more data will be presented at similar upcoming events as the phase 1 studies proceed. In regulatory toxicity studies, our compounds have been well tolerated and shown a good safety profile.”
ohisay
25/8/2017
10:55
Good news for Pharmaxis.. h t t p://www.proactiveinvestors.com.au/companies/stocktube/7997/pharmaxis-gets-a27m-injection-from-boehringer-ingelheim-7997.html
hutch_pod
28/7/2017
08:26
hxxp://www.pharmaxis.com.au/investor-centre/news/view/shareholder-update-june-2017 Large pharma company interest The role of LOXL2 in fibrotic diseases such as NASH and pulmonary fibrosis is of significant interest to many large pharma companies as its inhibition is one of the very few truly anti‐fibrotic mechanisms in clinical development. The annual US BIO conference in June 2017 provided an opportunity to share updates with them on our scientific progress and the timing of our partnering process which we plan to initiate in the second half of 2017 and conclude with a partnering deal in 2018..
ohisay
19/6/2017
21:24
Bought another 20k today at 8.5p Lets say cash is around 3m£ that leaves EV at 4.5m£ which is just too low in spite of all the setbacks recently . We are expecting news on INFB by mid July latest as per the finncap note above . They are not in a good place as regards raising cash /implied dilution but they are so undervalued at 8p odd I think a bid cannot be discounted.And Woodford would be up for that i think.
ohisay
18/5/2017
08:05
Thanks ohisay, that's helpful and strengthens my resolve to hang on. It looks like they are going to be looking at beta-interferon for COPD now, which seems to makes commercial sense assuming the science stacks up. I wonder what the IP position is on COPD, especially given that Faron's active interest in beta-interferon for ADRS? I will ask the question when I get a chance.
timbo003
18/5/2017
03:56
http://www.proactiveinvestors.co.uk/companies/news/177900/synairgen-pleased-with-the-progress-made-with-the-loxl2-programme-177900.html House broker finnCap said the cash position was some £1.2mln higher than expected, which it put down to lower research & development costs, which were timing related, and better than expected working capital. “As indicated in late April, Synairgen intends to conduct a thorough analysis of all data arising from the AZ Phase IIa study with the intention of providing an update in the next 1-2 months. The possibility of using inhaled Interferonbeta (IFN-beta) in COPD, given recently published data indicating the link between colds and exacerbations in COPD, suggests the analysis to be warranted,” opined finnCap. “Target price remains under review, pending outcome of analysis,” finnCap revealed. “Suffice to say, the progress of LOXL2 into Phase I is a valuation inflection point in itself, worth as much as 5-10p per share but excluding any upfront payments,” it added.
ohisay
17/5/2017
08:23
Not a bad update this morning I thought particularly in the ifnb area.. Bought 20k at 10.75p - looks a tad cheap to me. Furthermore on an objective measure we saw that treatment with inhaled IFN-beta resulted in an improved morning peak expiratory flow of 19.7L/min (p=0.01). The day-by-day changes in this parameter closely mirror the changes we observed in our Phase II study. Once again inhaled IFN-beta was well tolerated. ... We are particularly interested in using inhaled IFN-beta in COPD. Two new publications(1,2) in 2017 have shown that cold viruses are highly likely to cause exacerbations in COPD, which contrasts with the findings in asthma from the INEXAS trial, where only around 10% of patients exacerbated during cold infections. There is also a greater clinical need in COPD compared to asthma as exacerbations in COPD patients are linked to a rapid and permanent deterioration of disease and death. New technology has recently emerged which will enable us to confirm viral infection prior to commencing treatment, making trial management and interpretation easier. Thus the new data linking viruses to exacerbations, a better understanding of the underlying biology in COPD, the high clinical need, and new diagnostic technology presents us with an attractive opportunity to explore the drug's full potential.
ohisay
05/5/2017
14:49
the 3 year share price graph looks tragic!! i followed neil woodford in but thankfully left with a small loss....
nakedsteve
05/5/2017
13:08
The short answer is Yes ! Putting the current issues regarding the results of the Astra P11 Clinical trial to one side..the following from the SNG latest Presentation (March 2017) is very interesting...and subject to successful completion of Toxicology testing .. Phase I clinical trials scheduled to start in H2 2017.. Whilst again no Guarantee's of success here can be taken it is worth looking at the potential .. and it is significant of revenue that could be earned by SNG's involvement ... The slide below gives details of deals around Fibrosis struck with Pharma Majors. They are very significant in monetary terms... It is worth I believe remaining on the bus to see the outcome of SNG Fibrosis journey.. For those wanting to see the full presentation.. hxxp://www.synairgen.com/media/1346/introduction-to-synairgen-march-2017v2.pdf Develop an anti-fibrotic LOXL2 inhibitor for Idiopathic Pulmonary Fibrosis (IPF) • High LOXL2 is associated with more rapid disease progression • Recent deal in Fibrosis include: o Discovery stage  Boehringer Ingelheim 2016 collaboration with Inventiva to develop targets for IPF. Deal value up to €170m plus tiered royalties o Phase I  Gilead buys Nimbus Therapeutics in 2016 for Liver fibrosis programme $0.4bn up front and up to $0.8bn future payments o Phase II  Allergan buys Tobira Therapeutics in 2016 for Liver fibrosis programme $0.6bn up front and up to $1.1bn future payments  Bristol-Myers Squibb enters an agreement in 2015 providing exclusive rights to acquire Promedior Inc for up to $1.25bn o Post approval  Roche acquired Intermune in 2014 for $8bn, main programme was pirfenidone for IPF, and other anti-fibrosis programmes
rosejs2
05/5/2017
12:25
is there any hope for synairgen?
nakedsteve
28/4/2017
14:03
If Woodford puts up any more cash - rather than cutting and running could well be in high coupon preference shares with blocking rights possibly similar to those used to further fund RM2 - but with all his problems with health development coys such as Allied Minds he might/should let them die.
pugugly
28/4/2017
13:19
I think the board needs to provide some more information. What were the preset criteria AZ used to assess the drug and was it able to meet them given the early halt to the trial? There's a big difference between bad data and too little data.Regardless, it's bad news. At a minimum, Synairgen has lost three years on the interferon, since any new partner will surely want a new P2. I agree with the comment above that it's now tainted and it'll be hard to find another partner, even if the science is still reasonably positive.
mirako
28/4/2017
10:57
MMS got this by the goolies people. They offloaded those 3.6m shs at 7p to punters above 13p. Don't leave much to the imagination what they are going to do now, compounding with the facts a fund raising will happen and high probability biggies will start cutting the holdings.
big bear billy
28/4/2017
08:20
Cash call at 6p, but they need to fast though. Sp is surely heading towards 10p now.
duck_and_dive
Chat Pages: 26  25  24  23  22  21  20  19  18  17  16  15  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170921 17:43:23